PNC Financial Services Group Inc. (The) Common Stock vs Regeneron Pharmaceuticals Inc — how do they compare? PNC Financial Services Group Inc. (The) Common Stock trades at $220 (market cap $86.86B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: PNC Financial Services Group Inc. (The) Common Stock and Regeneron Pharmaceuticals Inc are close in size by market cap, and PNC Financial Services Group Inc. (The) Common Stock pays the higher dividend (3.67%). Which is the better fit depends on your goals.
| PNC | REGN | |
|---|---|---|
Market Cap | $86.86B | $76.40B |
Volume | 2,044,725 | 626,381 |
Sector | Financials | Health |
52-Week High | $256.97 | $852.03 |
52-Week Low | $178.37 | $557.73 |
Enterprise Value | $143.85B | $71.12B |
Dividend Yield | 3.67% | 0.51% |
Typical Hold Time | — | 107 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
PNC Financial Services Group is a financial services holding company. Its businesses include retail banking, corporate and institutional banking, and asset management.
Read more on PNC →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →